Bioengineer.org news story
A new systematic review and meta-analysis published in Virology Journal has brought together the scattered clinical evidence on treating acute hepatitis C virus (HCV) infection with interferon-free, dual direct-acting antiviral (DAA) regimens, and the headline finding is striking: across fourteen studies encompassing 1,078 treated patients, the pooled rate of sustained virological response at twelve weeks after therapy (SVR12) — the standard benchmark for cure — reached 97.7 percent. The analysis also delivers a nuanced message about treatment duration. Cure rates climbed steadily as courses lengthened, from under 85 percent at four weeks to above 99 percent at eight weeks, suggesting that while ultra-short therapy remains tempting, eight weeks may represent the practical minimum for reliably eradicating recently acquired infection.
Read the full news story here.
Source : Bioengineer.org
Related HIV and Co-Infections News
-
TheBodyPro | What to know about hepatitis B when switching to tenofovir-sparing antiretroviral regimens
-
WHO/Europe | Albania and Armenia achieve hepatitis B control milestone, strengthening the WHO European Region’s path to elimination
-
[Report] ECDC | Prevention, testing and treatment services for migrant populations in relation to HIV, TB, viral hepatitis and STIs
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.